Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 3/6 |
Jilin Jian Yisheng Pharmaceutical Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥7.10 |
52 Week High | CN¥10.21 |
52 Week Low | CN¥5.20 |
Beta | 0.18 |
1 Month Change | 0.71% |
3 Month Change | -20.31% |
1 Year Change | -10.35% |
3 Year Change | 0.71% |
5 Year Change | -7.91% |
Change since IPO | -46.80% |
Recent News & Updates
Recent updates
Shareholder Returns
2566 | CN Pharmaceuticals | CN Market | |
---|---|---|---|
7D | -4.3% | -4.3% | -4.9% |
1Y | -10.4% | -11.8% | -16.6% |
Return vs Industry: 002566 exceeded the CN Pharmaceuticals industry which returned -11.8% over the past year.
Return vs Market: 002566 exceeded the CN Market which returned -16.6% over the past year.
Price Volatility
2566 volatility | |
---|---|
2566 Average Weekly Movement | 7.8% |
Pharmaceuticals Industry Average Movement | 7.0% |
Market Average Movement | 8.2% |
10% most volatile stocks in CN Market | 11.5% |
10% least volatile stocks in CN Market | 5.1% |
Stable Share Price: 002566's share price has been volatile over the past 3 months.
Volatility Over Time: 002566's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1997 | 1,764 | Xiaomin Xue | https://www.yisheng-pharm.com |
Jilin Jian Yisheng Pharmaceutical Co., Ltd. manufactures and sells medicine, Chinese herbal medicine, cosmetics, and ginseng products in China. The company offers injections, tablets, granules, hard capsules, mixtures, eye drops, liniments, liquors, syrups, emulsions, and other raw materials.
Jilin Jian Yisheng Pharmaceutical Co., Ltd. Fundamentals Summary
2566 fundamental statistics | |
---|---|
Market cap | CN¥2.32b |
Earnings (TTM) | CN¥81.23m |
Revenue (TTM) | CN¥858.26m |
28.9x
P/E Ratio2.7x
P/S RatioIs 2566 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
2566 income statement (TTM) | |
---|---|
Revenue | CN¥858.26m |
Cost of Revenue | CN¥233.30m |
Gross Profit | CN¥624.96m |
Other Expenses | CN¥543.73m |
Earnings | CN¥81.23m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Apr 19, 2024
Earnings per share (EPS) | 0.25 |
Gross Margin | 72.82% |
Net Profit Margin | 9.46% |
Debt/Equity Ratio | 20.5% |
How did 2566 perform over the long term?
See historical performance and comparison